<DOC>
	<DOCNO>NCT02536742</DOCNO>
	<brief_summary>This international , multicenter , randomize , double-blind , placebo-controlled , Phase II clinical trial primary objective demonstrating superiority palbociclib combination fulvestrant placebo plus fulvestrant prolonging progression free survival ( PFS ) post-menopausal woman hormone receptor positive , HER2-negative metastatic locally relapse breast cancer whose disease progress prior endocrine therapy ( 1st 2nd line ) .</brief_summary>
	<brief_title>Palbociclib Molecularly Characterized ER-positive/HER2-negative Metastatic Breast Cancer</brief_title>
	<detailed_description>Based efficacy data palbociclib preclinical clinical setting , hypothesize addition palbociclib fulvestrant result prolongation PFS woman ER positive , HER2 negative , endocrine pretreated , metastatic locally advanced breast cancer , compare PFS achieve placebo plus fulvestrant . The trial include AURORA program conduct Breast International Group ( BIG ) , international study aim collect characterize biological sample , include metastatic tissue , patient advance breast cancer . Detailed molecular information available identify putative biomarkers response study regimen . The trial provide important addition current knowledge predictive biomarkers palbociclib provide extensive molecular characterization metastatic disease circulate biomarkers might well suit retrospective biologic correlative study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Palbociclib</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<criteria>Female gender Age ≥ 18 year Postmenopausal , define woman : Prior bilateral surgical oophorectomy ; Amenorrhea age ≥ 60 year ; Age &lt; 60 year amenorrhea 12 consecutive month absence alternative pathological physiological cause FSH serum estradiol level within laboratory 's reference range postmenopausal woman . Endocrine resistant disease , define one : Relapse adjuvant endocrine therapy ; Relapse within 12 month completion adjuvant endocrine therapy ; Progression disease first line endocrine therapy metastatic and/or locoregionally advance breast cancer . Successful enrollment AURORA program BIG . ER positive tumor , assess AURORA central laboratory . HER2negative tumor , assess AURORA central laboratory . ECOG Performance Status 01 . Measurable nonmeasurable evaluable disease accord RECIST 1.1 . Written Informed Consent ( IC ) screening procedure . The patient inform agree data transfer handling , accordance national data protection guideline . Life expectancy &gt; 3 month . Hematological status : Absolute neutrophil count ≥ 1.5 × 109/L Platelet count ≥ 100 × 109/L Hemoglobin ≥ 9 g/dL Hepatic status : Serum total bilirubin ≤ 1.5 × upper limit normal ( ULN ) . AST ALT ≤ 2.5 × ULN ; patient liver metastasis , ALT AST must ≤ 5 × ULN . Glucose normal range , wellcontrolled diabetes define HbA1c level ≤ 7.5 % . Renal status : Creatinine ≤ 1.5 ×ULN creatinine clearance &gt; 60 ml/min . International Normalized Ratio ( INR ) Prothrombin Time ( PT ) ≤1.5 × ULN unless patient receive anticoagulant therapy long PT PTT within therapeutic range intend use anticoagulant . Ability swallow oral medication . Prior use fulvestrant CDK inhibitor . Prior chemotherapy metastatic locally relapsed disease . Previous current nonbreast malignancy within last 5 year , exception situ carcinoma cervix , adequately treat basal cell squamous cell carcinoma skin . Known active uncontrolled symptomatic CNS metastasis , carcinomatous meningitis leptomeningeal disease indicate clinical symptom , cerebral edema , and/or progressive growth . Any follow previous 6 month : myocardial infarction , severe/unstable angina pectoris , ongoing cardiac dysrhythmias NCI CTCAE grade ≥2 , atrial fibrillation grade , coronary/peripheral artery bypass graft , symptomatic congestive heart failure ( NYHA functional classification ≥3 ) , cerebrovascular accident include transient ischemic attack , symptomatic pulmonary embolism . QTc exceed 480msec , family personal history long short QT syndrome , Brugada syndrome know history QTc prolongation , Torsade de Pointes ( TdP ) . Uncontrolled electrolyte disorder reinforce QTprolonging effect drug ( e.g. , hypocalcemia , hypokalemia , hypomag¬nesemia ) . Known history HIV seropositivity . HIV screening require baseline . Uncontrolled diabetes define HbA1c level &gt; 7.5 % . Concurrent disease familial , sociological geographical condition would make patient inappropriate trial participation serious medical disorder would interfere patient 's safety . Dementia , alter mental status , psychiatric condition would prevent understand render Informed Consent . Known abnormalities coagulation bleed diathesis , treatment anticoagulant preclude intramuscular injection fulvestrant . Treatment investigational agent 4 week randomization . Concurrent treatment drug permit Adverse event ( except alopecia ) previous systemic cancer therapy , radiotherapy surgery recover CTCAE v4.0 grade 1 resolve prior randomization .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Metastatic</keyword>
	<keyword>Breast</keyword>
	<keyword>HER2 negative</keyword>
	<keyword>Palbociclib</keyword>
</DOC>